平均降幅超60%！第十批国采中选药品即将落地日照

Core Viewpoint - The implementation of the national centralized procurement policy will significantly enhance the quality of medication for patients and optimize the clinical medication structure, with an average price reduction exceeding 60% for the selected drugs [1][2]. Group 1: Centralized Procurement Details - The centralized procurement covers 62 types of drugs, addressing treatment areas such as hypertension, diabetes, tumors, cardiovascular diseases, infections, and mental illnesses [1]. - High-value drugs and clinically scarce drugs are included, such as Doxorubicin Liposome Injection for breast cancer and Norepinephrine Bitartrate Injection for clinical shortages [1]. - Over 50 drug varieties, including Terbutaline Sulfate Injection and Linagliptin Tablets, have price reductions exceeding 90% [1]. Group 2: Impact on Patient Care - The policy will promote the replacement of unapproved drugs with those that have passed the national quality and efficacy consistency evaluation, thereby improving medication safety and efficacy [2]. - For instance, Doxorubicin Liposome Injection significantly reduces the incidence of adverse reactions compared to traditional formulations, enhancing medication safety [2]. - The inclusion of Macitentan Tablets for pulmonary arterial hypertension provides more treatment options for rare disease patients [2]. - The promotion of combination formulations like Sitagliptin Metformin Tablets can enhance therapeutic effects and simplify medication regimens, improving patient adherence [2]. Group 3: Implementation Timeline - The procurement results for the national Chinese medicine decoction pieces will be implemented in Rizhao City starting April 21, 2025, with 45 varieties available for purchase in public medical institutions [2].